Literature DB >> 11562452

Subcellular distribution of epothilones in human tumor cells.

R B Lichtner1, A Rotgeri, T Bunte, B Buchmann, J Hoffmann, W Schwede, W Skuballa, U Klar.   

Abstract

Epothilones are a new class of natural and potent antineoplastic agents that stabilize microtubules. Although 12,13-epoxide derivatives are potent antiproliferative agents, the activities of the corresponding 12,13-olefin analogs are significantly decreased. These data were confirmed for two new analogs, 6-propyl-EpoB (pEB) and 6-propyl-EpoD (pED), in comparison with the natural compounds EpoB/EpoD, by using human A431, MCF7, and MDR1-overexpressing NCI/Adr cells. By using tritiated pEB/pED, compound uptake, release, and nuclear accumulation were investigated in A431 and NCI/Adr cells. In these cells, epothilones can principally be recognized and exported by Verapamil-sensitive efflux pumps, which are not identical to MDR1. The degree of export depends on the structure, olefin vs. epoxide-analog, and also on the intracellular drug concentration. The accumulation of pED used at 3.5 or 70 nM, respectively, was increased in the presence of 10 microM Verapamil in both cell lines 2- to 8-fold. In contrast, the intracellular levels of pEB were affected by Verapamil only at 3.5 nM pEB in NCI/Adr (2-fold) and not in A431 cells. In addition, strong nuclear accumulation was observed for pEB (40-50%) but not paclitaxel or pED (5-15%) in both cell lines. Our study suggests that differences in growth inhibitory efficacy between epoxide and olefin analogs may be based on different mechanisms of drug accumulation and subcellular distribution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562452      PMCID: PMC58800          DOI: 10.1073/pnas.171023398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity.

Authors:  K H Altmann; M Wartmann; T O'Reilly
Journal:  Biochim Biophys Acta       Date:  2000-05-17

2.  Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.

Authors:  P Giannakakou; D L Sackett; Y K Kang; Z Zhan; J T Buters; T Fojo; M S Poruchynsky
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

3.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

Authors:  T C Chou; X G Zhang; C R Harris; S D Kuduk; A Balog; K A Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  New synthetic inhibitors of microtubule depolymerization.

Authors:  U Klar; H Graf; O Schenk; B Röhr; H Schulz
Journal:  Bioorg Med Chem Lett       Date:  1998-06-02       Impact factor: 2.823

5.  Quantification of cells cultured on 96-well plates.

Authors:  W Kueng; E Silber; U Eppenberger
Journal:  Anal Biochem       Date:  1989-10       Impact factor: 3.365

Review 6.  Structure and utilization of tubulin isotypes.

Authors:  K F Sullivan
Journal:  Annu Rev Cell Biol       Date:  1988

7.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.

Authors:  P Giannakakou; R Gussio; E Nogales; K H Downing; D Zaharevitz; B Bollbuck; G Poy; D Sackett; K C Nicolaou; T Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol.

Authors:  S Rao; L He; S Chakravarty; I Ojima; G A Orr; S B Horwitz
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

9.  The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.

Authors:  L Sepp-Lorenzino; A Balog; D-S Su; D Meng; N Timaul; H I Scher; S J Danishefsky; N Rosen
Journal:  Prostate Cancer Prostatic Dis       Date:  1999-01       Impact factor: 5.554

10.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

Authors:  M A Jordan; K Wendell; S Gardiner; W B Derry; H Copp; L Wilson
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

View more
  6 in total

1.  Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton.

Authors:  A Dietzmann; D Kanakis; E Kirches; S Kropf; C Mawrin; K Dietzmann
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

Review 2.  Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives.

Authors:  Karl-Heinz Altmann; Fabienne Z Gaugaz; Raphael Schiess
Journal:  Mol Divers       Date:  2011-01-01       Impact factor: 2.943

3.  Radiosensitizing effect of epothilone B on human epithelial cancer cells.

Authors:  T Baumgart; G Klautke; S Kriesen; S A Kuznetsov; D G Weiss; R Fietkau; G Hildebrandt; K Manda
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

4.  The subcellular distribution of small molecules: a meta-analysis.

Authors:  Nan Zheng; Hobart Ng Tsai; Xinyuan Zhang; Kerby Shedden; Gus R Rosania
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

5.  Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.

Authors:  Sebastian Winsel; Anette Sommer; Julia Eschenbrenner; Kevin Mittelstaedt; Ulrich Klar; Stefanie Hammer; Jens Hoffmann
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.

Authors:  Julia Eschenbrenner; Sebastian Winsel; Stefanie Hammer; Anette Sommer; Kevin Mittelstaedt; Michael Drosch; Ulrich Klar; Christoph Sachse; Michael Hannus; Monika Seidel; Bertram Weiss; Claudia Merz; Gerhard Siemeister; Jens Hoffmann
Journal:  Front Oncol       Date:  2011-11-16       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.